Document is current
Any future updates will be listed below
-
Authors
Zekri, Latifa https://orcid.org/0000-0002-9844-7948
Vogt, Fabian
Osburg, Lukas
Müller, Stefanie
Kauer, Joseph https://orcid.org/0000-0003-1632-0167
Manz, Timo
Pflügler, Martin
Maurer, Andreas
Heitmann, Jonas S
Hagelstein, Ilona
Märklin, Melanie
Hörner, Sebastian
Todenhöfer, Tilmann
Calaminus, Carsten
Stenzl, Arnulf
Pichler, Bernd
la Fougère, Christian
Schneider, Marc A
Rammensee, Hans‐Georg
Zender, Lars
Sipos, Bence
Salih, Helmut R https://orcid.org/0000-0002-6719-1847
Jung, Gundram https://orcid.org/0000-0002-2831-2829
-
Funding
Funding for this research was provided by:
Helmholtz validation fund (HVF55)
Deutsche Forschungsgemeinschaft (SA1360/9‐1)
Deutsche Forschungsgemeinschaft (SA1360/7‐3)
Wilhelm Sander‐Stiftung (2007.115.3)
Deutsche Krebshilfe (111828)
Deutsche Krebshilfe (70112914)
Germany's Excellence Strategy (EXC 2180/1)
- License Information
-
More Information
Article History
Received: 13 December 2019
Revised: 26 November 2020
Accepted: 1 December 2020
First Online: 29 December 2020
Conflict of interest
: GJ, HS, FV, and LatZ are listed as inventors on the patent application “Novel PSMA binding antibody and uses thereof,” EP16151281, applicant German Cancer Research Center, Heidelberg, Germany.
